These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1320557)

  • 1. Cutoff assignment strategies for enhancing randomized clinical trials.
    Trochim WM; Cappelleri JC
    Control Clin Trials; 1992 Jun; 13(3):190-212. PubMed ID: 1320557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An illustrative statistical analysis of cutoff-based randomized clinical trials.
    Cappelleri JC; Trochim WM
    J Clin Epidemiol; 1994 Mar; 47(3):261-70. PubMed ID: 8138836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical and scientific features of cutoff-based designs of clinical trials: a simulation study.
    Cappelleri JC; Trochim WM
    Med Decis Making; 1995; 15(4):387-94. PubMed ID: 8544682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diazepam versus alprazolam for the treatment of panic disorder.
    Noyes R; Burrows GD; Reich JH; Judd FK; Garvey MJ; Norman TR; Cook BL; Marriott P
    J Clin Psychiatry; 1996 Aug; 57(8):349-55. PubMed ID: 8752017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The regression discontinuity design showed to be a valid alternative to a randomized controlled trial for estimating treatment effects.
    Maas IL; Nolte S; Walter OB; Berger T; Hautzinger M; Hohagen F; Lutz W; Meyer B; Schröder J; Späth C; Klein JP; Moritz S; Rose M
    J Clin Epidemiol; 2017 Feb; 82():94-102. PubMed ID: 27865902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation reactions to alprazolam in panic disorder.
    Pecknold JC
    J Psychiatr Res; 1993; 27 Suppl 1():155-70. PubMed ID: 8145176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using severity rather than randomization for assignment in clinical trials: Monte Carlo tests and practical illustrations of the Robbins-Zhang method.
    Ross DC
    J Psychiatr Res; 1995; 29(4):315-32. PubMed ID: 8847658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.
    Ravaris CL; Friedman MJ; Hauri PJ; McHugo GJ
    J Clin Psychopharmacol; 1991 Dec; 11(6):344-50. PubMed ID: 1770152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.
    Moylan S; Staples J; Ward SA; Rogerson J; Stein DJ; Berk M
    J Clin Psychopharmacol; 2011 Oct; 31(5):647-52. PubMed ID: 21869686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to alprazolam and placebo in patients with panic disorder.
    Woodman CL; Noyes R; Ballenger JC; Lydiard RB; Sievers G; Mihalko D
    J Affect Disord; 1994 Jan; 30(1):5-13. PubMed ID: 8151049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.
    Br J Psychiatry; 1992 Feb; 160():191-202; discussion 202-5. PubMed ID: 1540759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
    Schweizer E; Patterson W; Rickels K; Rosenthal M
    Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.
    Keller MB; Lavori PW; Goldenberg IM; Baker LA; Pollack MH; Sachs GS; Rosenbaum JF; Deltito JA; Leon A; Shear K
    J Affect Disord; 1993 May; 28(1):27-38. PubMed ID: 8326078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression Discontinuity Design: Simulation and Application in Two Cardiovascular Trials with Continuous Outcomes.
    van Leeuwen N; Lingsma HF; de Craen AJ; Nieboer D; Mooijaart SP; Richard E; Steyerberg EW
    Epidemiology; 2016 Jul; 27(4):503-11. PubMed ID: 27031038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy studies of alprazolam in panic disorder.
    Spiegel DA
    Psychopharmacol Bull; 1998; 34(2):191-5. PubMed ID: 9640999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personality dimensions in panic disorder before and after effective treatment.
    Starcevic V; Uhlenhuth EH
    Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
    [No Abstract]   [Full Text] [Related]  

  • 18. Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam.
    Bond AJ; Curran HV; Bruce MS; O'Sullivan G; Shine P
    J Affect Disord; 1995 Dec; 35(3):117-23. PubMed ID: 8749839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder.
    Woods SW; Nagy LM; Koleszar AS; Krystal JH; Heninger GR; Charney DS
    J Clin Psychopharmacol; 1992 Feb; 12(1):32-8. PubMed ID: 1552038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug treatment of panic disorder.
    Rosenberg R
    Pharmacol Toxicol; 1993 Jun; 72(6):344-53. PubMed ID: 8103214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.